Aratana Therapeutics Seeks Fourth FDA Approval

Aratana submitted a supplemental New Animal Drug Application (NADA) for NOCITA® (bupivacaine liposome injectable suspension) with the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM). The filing is the Company's fourth filing for FDA-approval and is intended to expand the label for their FDA-approved therapeutic to include its use as a specific type of non-opioid analgesic in cats. The therapeutic was FDA-approved in August 2016 in dogs to provide up to 72 hours of post-operative pain relief following knee surgery.

"We believe veterinarians are in need of safe and effective, non-opioid alternatives to provide pain relief to their feline and canine patients" explained Ernst Heinen, DVM, PhD, Chief Development Officer of Aratana Therapeutics. "If the supplemental NADA is approved, NOCITA will help control feline pain for up to 72 hours by blocking pain signals at their source, the nerve."